Back

VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

iwMyeloma 2017 | Genetic elements driving IMiD resistance in multiple myeloma

Benjamin Barwick • 18 Oct 2017

Immunomodulatory drugs (IMiDs) are a class of drugs including the likes of thalidomide, which are used in the treatment of cancers such as multiple myeloma (MM). In this interview, recorded at the Myeloma 2017 meeting in Edinburgh, UK, Benjamin Barwick, PhD, of Emory University, Atlanta, GA, discusses the talks given at the meeting which discussed IMiDs, and how resistance to them in MM can be driven by various enhancers and transcription factors that lead to worse outcomes for patients.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter